Nav: Home

Bonnie J. Addario Lung Cancer Foundation and IASLC announce joint award

March 01, 2016

SAN CARLOS, Calif. (March 1, 2016) -- The Bonnie J. Addario Lung Cancer Foundation (ALCF) and the International Association for the Study of Lung Cancer (IASLC) today announced the first ever $300,000 ALCF-IASLC Joint International Fellowship Award for The Early Detection of Lung Cancer to Robin Mjelle, PhD, researcher at the Department of Cancer Research and Molecular Medicine at the Norwegian University of Science and Technology (NTNU).

The ALCF-IASLC Joint Fellowship Award supports novel, innovative and translational research with the potential of having a high clinical impact on the early detection of lung cancer. Dr. Mjelle is working on the identification, characterization and validation of biomarkers for the early detection of lung cancer.

"This first joint award between the ALCF and IASLC funds research that will positively impact lung cancer patients. Dr. Mjelle is a young, talented researcher whose dedication to lung cancer research is truly remarkable," said Bonnie J. Addario, 10-year lung cancer survivor and founder of the ALCF. "As the first awardee of the ALCF-IASLC Fellowship, Dr. Mjelle will be able to continue his research on early detection and diagnosis of lung cancer. This grant allows him to travel and train at a lab of his choice anywhere in the world to solve problems related to early detection of lung cancer."

The prospective population-based HUNT2 and HUNT3 studies in Norway included 80,000 people with 190 clinical variables and blood samples collected during1996-7 and 2006-8 (http://www.ntnu.edu/hunt). For 65,000 participants there is more than 15 years follow-up, where more than 500 participants were subsequently diagnosed with lung cancers, where diagnosis, diagnosis date and date of death of all subjects are known. Using this cohort, Dr. Mjelle and colleagues plan to develop a risk-prediction tool that will help the development of a serum poly-marker kit.

"Detection of lung cancer in the earliest possible stage is currently the only path to increase survival. The project "Cancer Biomarkers in HUNT" aims to develop a blood-based biomarker for early lung cancer detection," said Dr. Mjelle. "The project uses pre-diagnostic serum samples from the HUNT biobank in Norway to measure RNA, proteins and metabolites in lung cancer patients and healthy controls. Having access to blood 1-5 years before diagnosis makes this project unique and enables the detection of biomarkers that could predict the cancer when it is still in curable stage. The 2016 ALCF-IASLC Fellowship Award will greatly benefit the progress of the project."

ALCF and IASLC received several promising submissions from researchers all over the world proposing innovative research projects on new modalities for the early detection of lung cancer. An international scientific peer review committee established by ALCF and IASLC reviewed these applications and unanimously chose Dr. Robin Mjelle as the recipient of the 2016 award.

"The work of Dr. Mjelle is recognized through this award because of the potential long-term impact of his research," said Dr. Fred R. Hirsch, MD, PhD, Professor of Medicine and Pathology at the University of Colorado Cancer Center and CEO of the IASLC. "Determining risk of developing lung cancer is empowering to the individual and can help in screening for lung cancer so early treatment and disease management can be achieved."

Known for his unsurpassed research on biomarkers for early detection and new treatments for lung cancer himself, Dr. Hirsch joined the University of Colorado Cancer Center as a Professor of Medicine in 2000 and as a Professor of Pathology in 2004.

The objective of this new ALCF-IASLC funding mechanism is to identify brilliant, young "out of the box" thinkers/researchers who can deliver a meaningful and measurable results for the early detection of lung cancer that has a high probability of near-term benefit to lung cancer patients or individuals at risk, as well as to provide an opportunity for young researchers to learn new cutting-edge technologies and take this expertise back to their home country.
-end-
Learn more about this funding opportunity: https://www.lungcancerfoundation.org/research/fellowships/.

Learn more about Dr. Robin Mjelle's proposal: https://www.lungcancerfoundation.org/research/fellowships/.

About the Bonnie J. Addario Lung Cancer Foundation:

The Bonnie J. Addario Lung Cancer Foundation (ALCF) is one of the largest philanthropies (patient-founded, patient-focused, and patient-driven) devoted exclusively to eradicating Lung Cancer through research, early detection, education, and treatment. The Foundation's goal is to work with a diverse group of physicians, organizations, industry partners, individuals, patients, survivors, and their families to identify solutions and make timely and meaningful change and turn lung cancer into a chronically managed disease by 2023. The ALCF was established on March 1, 2006 as a 501c(3) non-profit organization and has raised nearly $25 million for lung cancer research and related programs.

About International Association for the Study of Lung Cancer:

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer. Founded in 1974, the association's membership includes more than 5,000 lung cancer specialists in over 100 countries. IASLC members promote the study of etiology, epidemiology, prevention, diagnosis, treatment and all other aspects of lung cancer and thoracic malignancies. IASLC brings scientists, members of the medical community and the public together from all over the world to share best practices and discover new and better ways to eliminate the health threat of thoracic cancers. Membership is open to any physician, scientist, nurse or allied health professional interested in lung cancer and other thoracic malignancies, including patients, survivors, caregivers and advocates. Visit http://www.iaslc.org for more information and follow us on Twitter @IASLC.

International Association for the Study of Lung Cancer

Related Lung Cancer Articles:

'Social smokers' face disproportionate risk of death from lung disease and lung cancer
'Social smokers' are more than twice as likely to die of lung disease and more than eight times as likely to die of lung cancer than non-smokers, according to research presented at the European Respiratory Society International Congress.
Lung cancer therapy may improve outcomes of metastatic brain cancer
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St.
Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.
Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.
Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.
Better equipped in the fight against lung cancer
Lung cancer is the third most common type of cancer in Germany and the disease affects both men and women.
New liquid biopsy-based cancer model reveals data on deadly lung cancer
Small cell lung cancer (SCLC) accounts for 14 percent of all lung cancers and is often rapidly resistant to chemotherapy resulting in poor clinical outcomes.
Cancer drug leads to 'drastic decrease' in HIV infection in lung cancer patient
Doctors in France have found the first evidence that a cancer drug may be able to eradicate HIV-infected cells in humans.
More Lung Cancer News and Lung Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: The Power Of Spaces
How do spaces shape the human experience? In what ways do our rooms, homes, and buildings give us meaning and purpose? This hour, TED speakers explore the power of the spaces we make and inhabit. Guests include architect Michael Murphy, musician David Byrne, artist Es Devlin, and architect Siamak Hariri.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

What If?
There's plenty of speculation about what Donald Trump might do in the wake of the election. Would he dispute the results if he loses? Would he simply refuse to leave office, or even try to use the military to maintain control? Last summer, Rosa Brooks got together a team of experts and political operatives from both sides of the aisle to ask a slightly different question. Rather than arguing about whether he'd do those things, they dug into what exactly would happen if he did. Part war game part choose your own adventure, Rosa's Transition Integrity Project doesn't give us any predictions, and it isn't a referendum on Trump. Instead, it's a deeply illuminating stress test on our laws, our institutions, and on the commitment to democracy written into the constitution. This episode was reported by Bethel Habte, with help from Tracie Hunte, and produced by Bethel Habte. Jeremy Bloom provided original music. Support Radiolab by becoming a member today at Radiolab.org/donate.     You can read The Transition Integrity Project's report here.